An FDA-cleared biomarker test for pediatric acute kidney injury risk assessment based on NGAL detection. It is the first FDA-cleared biomarker test for this indication and is available for use on the Cobas c 501 clinical chemistry analyzer through Roche Diagnostics.
Manufactured by
United States
ProNephro AKI (NGAL) is designed to aid in the risk assessment of acute kidney injury (AKI) in ICU patients 3 months to 22 years. A low NGAL value indicates a low risk of AKI, allowing for confident use of interventions such as fluids, diuretics, or nephrotoxic medications. Elevated NGAL values signal a high risk of developing AKI and can trigger nephrology consults and interventions 2-3 days before serum creatinine rises.
✦ Product-Specific Coverage
Based on AI-matched alternatives related to this product across Suplivia's medical sourcing network.
Generated for this product
AI-matched supplier coverage based on related product alternatives.
Micropoint Bioscience, Inc.
United States · 4 relevant products
Shenzhen Kingfocus Biomedical Engineering Co., Ltd.
China · 2 relevant products
Bio Preventive Medicine Co. Ltd.
Taiwan · 6 relevant products
NewScen Coast Bio-Pharmaceutical Co., Ltd.
China · 5 relevant products
Hangzhou Elit Biotech Co.,Ltd.
China · 1 relevant product
GenSure Biotech Inc.
China · 1 relevant product
ARGERON MEDİKAL ARAŞ.SAN.VE TİC.A.Ş.
Türkiye · 2 relevant products
Anhui Huibang Biological Engineering Co., Ltd.
China · 7 relevant products
Randox Laboratories Ltd.
United Kingdom · 2 relevant products
PRIMA Lab SA
Switzerland · 2 relevant products
57 more relevant manufacturers available
Get free access to all relevant manufacturers for this product.
See all manufacturers →6 more sourcing countries available
Get free access to all sourcing countries identified for this product.
See all countries →See the full supplier coverage for this product
Get free access to all relevant manufacturers, sourcing countries, and product alternatives.
✓ Free for medical industry professionals.
from other manufacturers
from other manufacturers
12 of 102 closest product alternatives
Micropoint Bioscience, Inc. · United States
A point-of-care diagnostic test device for measuring neutrophil gelatinase-associated lipocalin (NGAL), a biomarker for kidney injury assessment. Based on microfluidic technology for rapid clinical testing.
Shenzhen Kingfocus Biomedical Engineering Co., Ltd. · China
Diagnostic assays for detection of kidney injury markers in serum and urine samples. Enables early identification and monitoring of acute and chronic renal dysfunction.
Bio Preventive Medicine Co. Ltd. · Taiwan
A non-invasive urine-based diagnostic test designed to predict rapid kidney function deterioration in chronic kidney disease patients. This biomarker assay provides quantitative risk assessment to support early clinical intervention and disease management.
NewScen Coast Bio-Pharmaceutical Co., Ltd. · China
A diagnostic reagent kit for detecting neutrophil gelatinase-associated lipocalin using colloidal gold immunochromatography method. This test is used for kidney injury assessment.
Hangzhou Elit Biotech Co.,Ltd. · China
A rapid diagnostic test for the detection of Neutrophil Gelatinase-Associated Lipocalin (NGAL), a biomarker used in clinical assessment.
Bio Preventive Medicine Co. Ltd. · Taiwan
An in vitro diagnostic test that predicts the risk of rapid renal function decline in diabetic kidney disease patients. This urine-based biomarker test provides early risk assessment before symptomatic deterioration occurs, enabling timely clinical intervention.
GenSure Biotech Inc. · China
Diagnostic test kit for measurement of kidney function biomarkers including creatinine and urea. Facilitates assessment of renal function and detection of kidney disease.
ARGERON MEDİKAL ARAŞ.SAN.VE TİC.A.Ş. · Türkiye
A diagnostic test that measures urinary trehalase enzyme activity to help identify kidney injury earlier than conventional indicators. It offers early injury signal detection via trehalase activity, is compatible with standard analyzers, and provides fast, practical and highly sensitive results supporting clinical research.
Anhui Huibang Biological Engineering Co., Ltd. · China
An in vitro detection system for early diagnosis indicators of diabetic nephropathy in human urine. It features multi-channel composite detection with selected indicator combinations including urinary microalbumin, urinary haptoglobin, and urinary creatinine as an internal standard. The system uses dry biochemistry and immunology methods, allows random urine self-testing without invasive procedures, and supports home-based testing with mobile device image upload for server analysis and professional feedback.
Randox Laboratories Ltd. · United Kingdom
Testing solutions and biomarkers for acute kidney injury diagnosis and monitoring. These products support early detection and management of acute kidney injury in clinical laboratories.
Bio Preventive Medicine Co. Ltd. · Taiwan
The world's first in vitro diagnostic (IVD) test for predicting kidney disease progression. It effectively predicts the risk of rapid renal function decline in patients with diabetic kidney disease. The test is non-invasive, urine-based, and highly accurate, providing precise and effective predictive information before symptoms appear or rapid deterioration of kidney function occurs. DNlite has obtained EU IVDR certification and is market-authorized in over 42 countries worldwide.
Anhui Huibang Biological Engineering Co., Ltd. · China
In vitro diagnostic system for early detection of diabetic kidney disease through urine analysis. Combines dry-reagent technology with multi-channel detection of key biomarkers including urine microalbumin, uromodulin, and creatinine. Enables both clinical laboratory quantitative analysis and point-of-care home testing with mobile result upload and remote interpretation.
90 more product alternatives available
Create a free account to compare more product alternatives and supplier options.
© 2026 Suplivia · Home · Browse Products